What's hot

View all perspectives
What's Hot

Precision Immunotherapy in Axial SpA

Dr. Marina Magrey at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

PsA: Impact of Sex

Dr. Arthur Kavanaugh discusses abstracts 1709 and 1471, along with a related seminar, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

Cycling vs Switching after TNFi Failure in axSpA

Dr. Lihi Eder discusses abstract 0603, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

A Fibroblast Renaissance

Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →
men and women

ICYMI: Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

Read more →

Palliative Care in Rheumatology

Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

Efficacy and Safety of Nipocalimab for Sjogren's Syndrome

Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS), presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →
PMR,flag

ICYMI: Say Goodbye to Methotrexate in PMR?

For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.

Read more →

Predicting Flares in Rheumatoid Arthritis

Dr. Jonathan Kay interviews Dr. John Isaacs about abstract 1349, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →
statin

ICYMI: ORAL Surveillance - Is Statin Use the Problem/Solution?

The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.

Read more →
      IV or inhaled THC:
      Works quickly with high peak, feel euphoric but not sustained response
      Oral is much better for medici

      Eric Dein ericdeinmd

      1 year 1 month ago
      IV or inhaled THC: Works quickly with high peak, feel euphoric but not sustained response Oral is much better for medicinal usage @RheumNow #ACR24 https://t.co/3PatgEFjZh https://t.co/wrrLMpfL5D
      Cool data from the JAK-POT study

      Have heard JAKs faster than TNF; perhaps not the case!

      If anything, TNFs outperformed

      Mike Putman EBRheum

      1 year 1 month ago
      Cool data from the JAK-POT study Have heard JAKs faster than TNF; perhaps not the case! If anything, TNFs outperformed the others in this study Trying not to over-read this, but supports my re-emerging preference for TNF #ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds
      How to take cannabis?
      Do NOT rec inhaled
      - makes drug level go up high/fast, benefit for rec use but not for medicinal
      -

      Eric Dein ericdeinmd

      1 year 1 month ago
      How to take cannabis? Do NOT rec inhaled - makes drug level go up high/fast, benefit for rec use but not for medicinal - bronchitis, ?oral cancer Other risks: psychosis - risk in youth, memory loss (poor studies), dependence, respiratory if inhaled Clauw 16S18 #ACR24 @RheumNow https://t.co/coYNl7VOT3
      #0513
      🔬 Rituximab in RA: IgG levels & infection

      ➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs)

      Caoilfhionn Connolly CaoilfhionnMD

      1 year 1 month ago
      #0513 🔬 Rituximab in RA: IgG levels & infection ➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs) 🧬 IgG levels ⬇️over time (6 years/25 infusions) ⚠️ Infection-related hospitalizations peaked year 1 ⬆️risk w/ concurrent steroid(HR 2.1,p=0.002) #ACR24 @RheumNow
      Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is

      Jiha Lee JihaRheum

      1 year 1 month ago

      Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7

      Discrimination in #SLE is a chronic stressor - Asians had substantial levels along with association of worse mental heal

      Bella Mehta bella_mehta

      1 year 1 month ago
      Discrimination in #SLE is a chronic stressor - Asians had substantial levels along with association of worse mental health and SLE activity Data from the California Lupus Epidemiology Study (CLUES) using the Everyday Discrimination Scale (EDS) @JYazdany @RheumNow #ACR24 abst#0171
      Clauw: think of THC and CBD as “completely different”
      Cannabidiol - safe, not psychoactive, “can use liberally”

      Eric Dein ericdeinmd

      1 year 1 month ago
      Clauw: think of THC and CBD as “completely different” Cannabidiol - safe, not psychoactive, “can use liberally” THC - psychoactive with effects on CB1 and CB2 receptors. CB1 affects the brain where CB2 is more in inflammation #ACR24 @RheumNow https://t.co/A0TgSpAO64
      Cardiology 🤝 Rheumatology
      #Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associat

      Akhil Sood MD AkhilSoodMD

      1 year 1 month ago
      Cardiology 🤝 Rheumatology #Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort @RheumNow #ACR24 https://t.co/jLLYNOfFZ2
      Moderating a great talk about POTS - great slide & nice presentation technique

      Dr. Adler flashed a screen of the R

      Mike Putman EBRheum

      1 year 1 month ago
      Moderating a great talk about POTS - great slide & nice presentation technique Dr. Adler flashed a screen of the ROS for pts w/POTs, overwhelming as expected… then overlaid common causes and phenotypes - really like this as a framework! #ACR24 @RheumNow https://t.co/mCmtygxxv4
      🚨Therapeutic target in PsO?
      Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO).
      - HR-

      Adela Castro AdelaCastro222

      1 year 1 month ago
      🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI
      Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhanc

      Antoni Chan MD (Prof) synovialjoints

      1 year 1 month ago
      Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis. Another innovation that may help with the rapid… https://t.co/qSwryK22uj
      #0456📱 Digital Health & RA ePROs

      💻Rx response in 150 RA patients using ePROs & actigraphy

      🔍Actigraph

      Caoilfhionn Connolly CaoilfhionnMD

      1 year 1 month ago
      #0456📱 Digital Health & RA ePROs 💻Rx response in 150 RA patients using ePROs & actigraphy 🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone) 💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden. #ACR24 @RheumNow
      🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
      -Switching to IL1

      Adela Castro AdelaCastro222

      1 year 1 month ago
      🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI
      Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (includ

      Akhil Sood MD AkhilSoodMD

      1 year 1 month ago
      Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk. @RheumNow #ACR24
      Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease contr

      Akhil Sood MD AkhilSoodMD

      1 year 1 month ago
      Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×